Breaks Categories: News

TuesdayDec 21, 2021 11:50 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming January Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in two premier events: the 11th annual LifeSci Partners Annual Corporate Access Event and the H.C. Wainwright Bioconnect Conference. Cybin CEO Doug Drysdale will participate in both upcoming virtual investor events. At the LifeSci Partners event, scheduled for Jan. 5–7, 2021, Drysdale will be involved in a panel discussion titled “Psychedelics: More Than Just a Trip.” The panel is slated for Wednesday, Jan. 5, at 10 a.m. ET. At the H.C. Wainwright Bioconnect Conference, Drysdale willparticipate in a fireside chat, which is scheduled…

Continue Reading

FridayDec 17, 2021 2:26 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Advancing MYCO-001 to Bring Safer, More Effective Smoking Cessation Treatment to Market

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today published a blog article discussing positive clinical data assessing psilocybin for smoking cessation and its upcoming clinical trials. The piece, titled “Why We’re Bullish on MYCO-001, 99% Psilocybin, to Treat Nicotine Dependance,” covers Mydecine’s partnership with Dr. Matthew Johnson and Johns Hopkins University to advance its lead drug candidate MYCO-001 as a smoking cessation treatment. The company’s phase 2/3 smoking cessation clinical trial, set to launch in early 2022, builds from Dr. Johnson’s previous research…

Continue Reading

ThursdayDec 16, 2021 12:58 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Co-Founder, CEO Featured on ‘Gamechangers LIVE’

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, was featured in a recent episode of Gamechangers LIVE, a podcast series that shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. Delic’s CEO and Co-Founder Matt Stang joined the broadcast, hosted by Executive Coach and Speaker Sergio Tigera, to discuss his background in the alternative drugs sector, the groundswell of clinical and regulatory developments relating to psychedelics and how Delic is supporting those advancements through its portfolio of…

Continue Reading

ThursdayDec 16, 2021 10:10 am

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Announces Significant Milestone That Brings iSTRYM Closer to Commercial Deployment

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, today announced that the company and its digital therapeutics technology, iSTRYM, have been certified as Health Insurance Portability and Accountability Act (“HIPAA”) compliant. HIPAA compliance certification reflects MINDCURE’s commitment to achieving the highest standards of medical data protection and privacy and is the next step in working towards having the iSTRYM technology platform classified a “Software as a Medical Device” by the FDA. “Receiving HIPAA compliance is a significant milestone for MINDCURE, which supports our goal of commercially deploying iSTRYM…

Continue Reading

WednesdayDec 15, 2021 12:14 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notice of Allowance from U.S. Patent Office for Exclusive Anxiety Disorder Treatment

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”). The award is for CYBN’s patent application related to CYB004, an investigational deuterated psychedelic tryptamine compound developed for the potential treatment of anxiety disorders. According to the announcement, allowed claims under the award also include other forms of deuterated psychedelic tryptamine. This award expands Cybin’s intellectual property portfolio and strengthens the company’s position as leading innovator in developing putative psychedelic compounds. According to the company, CYB004 has the potential to effectively treat…

Continue Reading

FridayDec 10, 2021 12:24 pm

PsychedelicNewsBreaks – Mind Medicine (‘MindMed’) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) Engages with FDA for Development of the ‘MSMS’

Mind Medicine (“MindMed”) (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, recently met with the United States Food and Drug Administration (“FDA”) Center for Devices and Radiological Health (“CDRH”) with consultation from the Center for Drug Evaluation and Research (“CDER”). The device pre-submission meeting that took place on Oct. 25, 2021, was concerning several key points for ongoing development of the MindMed Session Monitoring System (“MSMS”). MindMed presented the FDA with a working Indications for Use (“IFU”) statement and a development roadmap, which describe technology and infrastructure for the collection of precise, multimodal, multivalent data…

Continue Reading

ThursdayDec 09, 2021 2:43 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Financing to Provide Runway for Key Milestones

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into an agreement with an investor to complete a non-brokered private placement (the “financing”) of a convertible secured subordinated debenture in the principal amount of C$5.5 million. According to the update, the financing is expected to close on Dec. 10, 2021. “I would like to thank our incredible strategic shareholder for stepping up in a tough, volatile market and continuing to support and expand upon your large stake in Mydecine,” said the…

Continue Reading

ThursdayDec 09, 2021 8:30 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Establishment of Regulatory Advisory Board, Strategic Appointments

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has formed a regulatory advisory board (“RAB”) and has appointed Joga Gobburu, B.Pharm (Hons), M.Sc. (Hons), Ph.D., M.B.A., and Mary Melnyk, M.Sc., Ph.D., as members. Dr. Gobburu is a world-recognized scientific leader in pharmacometrics and a professor at the School of Pharmacy and the School of Medicine at the University of Maryland. Dr. Melnyk is an expert in manufacturing and regulatory requirements for pharmaceutical and medical device development. She is the senior regulatory…

Continue Reading

WednesdayDec 08, 2021 11:38 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Moving Rapidly to Progress CYB003 Toward Clinical Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced a confirmed scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency (“MHRA”) for the first quarter of calendar year 2022. According to the update, this program milestone brings Cybin closer to advancing its lead investigational candidate CYB003 into clinical development for the treatment of major depressive disorder (“MDD”) and alcohol use disorder (“AUD”). “Encouraged by positive preclinical findings that demonstrated the advantages of our novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health, we are moving…

Continue Reading

MondayDec 06, 2021 12:24 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Patent Application Covering Multiple Families of Psilocin Analogs

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a full patent application covering multiple families of psilocin analogs. According to the update, the application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s active metabolite, both of which are critical for use in the medical setting. “The goal of creating these improved second-generation compounds is to enable safer, more effective treatments for patients along with improved management of dosage and drug behavior…

Continue Reading